Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum NervGen Pharma Corp NGENF


Primary Symbol: V.NGEN

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a... see more

TSXV:NGEN - Post Discussion

NervGen Pharma Corp > Wowza Wowza Pay attention before it's too late!
View:
Post by stargazer1 on Feb 02, 2024 6:17pm

Wowza Wowza Pay attention before it's too late!

NervGen Pharma Corp. (NGENF)

Things are happening behind the scenes. 
 
2.5900 + 0.4150 (+19.0805%) volume 105,701
At close: 4 PM EST
 
$2.61 + $0.4334 (+19.93%) volume post close 1,705
Post-market: 4:05 PM EST 02/02/2024
 
At 1:30 PM the stock was up only 0.04, and then the price took off with the chart climbing at a steady 45-degree angle. Volume also started picking up, especially as we neared the close of trading.
 
Stock was at 2.18 last night and it climbed almost half a dollar. That is a crazy amount. If someone had 10,000 shares, they made almost $5,000 today. I would guess that there are a lot of people here that have that many shares, or more.
 
Still no press release but considering previous press releases where test animals with severe spinal cord injuries started growing, not only new neurons, but branching neurons that could communicate with other neurons, and thus gave the animals regained mobility, I think that we are getting ready for a block buster press release.
I have been selling groups of my other stocks and buying NGENF for some time now. I won't sell over 50% of my stocks, just in case, and so I am finished buying. I accumulated 25,000 shares at an overall price of $2.03 a share.
 
I don't know when the company will give a press release. Legally they may have to wait until the end of their patient trial. But with the way the stock has been acting, people in the know may be acting on their knowledge. Things may be happening behind the scenes.

BUT the previous high in 2021 was $2.60 and at that time they didn't have all the animal trial results that we have. So, people couldn't really judge the company's possibilities.
 
This time around we are going to BLOW PAST THAT PREVIOUS HIGH. IN ONE DAY'S TIME WE ALREADY ALMOST DID THAT!
 
People, NOW IS THE LAST CHANCE YOU HAVE TO GET IN AT THESE PRICES. PLEASE CONSIDER IT!
 
Today I made $10,000. In another few weeks, or months, I may make more money that I ever have in an entire year of salary.
 
Hi ho, hi ho. It's off to work I go.
 
OR it could be a bad press release and I lose everything. So don't go in over your head, but if you can afford it, consider buying more shares Monday.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities